SAN DIEGO, Sept. 6, 2016 /PRNewswire/ — BioDuro, LLC, a global life science research and development organization today announced completion of a significant expansion to its 92,000 square foot Shanghai facility. The state-of-the-art facility, BioDuro’s second largest global site, is dedicated to meet today’s demands for fully integrated drug discovery and development, spanning computational and medicinal chemistry, DMPK, discovery biology, and pharmacology, all under one roof.
Expansions to the Shanghai facility include:
- Addition of a 6,000 square foot biology lab for discovery biology, oncology and pharmacology
- Additional capacity to accommodate 100 new chemists, capable of providing synthetic and medicinal chemistry services
- Scale-up facility of 6 walk-in hoods, enabling rapid processing of up to 5 kg of API
- An expanded bioanalytical lab space for non-GLP bioanalytical services with addition of a new API 6500 LC-MS/MS.
“With the completion and launch of this expansion, BioDuro Shanghai has now become a key site for our integrated drug discovery and development partnerships”, said TJ Deng, General Manager of BioDuro China. “From computational and medicinal chemistry, discovery biology, DMPK, pharmacology, non-GLP safety and process chemistry for IND enabling studies, BioDuro continues to enhance capabilities that will improve cycle times, and increase chances of success of therapeutic programs for BioDuro’s partners.”
Acquired in 2012, BioDuro’s Shanghai location has grown from a small business unit to now cutting edge facilities that include an 18,000 square foot vivarium and labs for ADME, bioanalysis, in vitro assays and translational research. Additional services at BioDuro Shanghai include process discovery, development and optimization. To learn more about BioDuro’s chemistry, biology, and integrated drug discovery services, visit www.bioduro.com or contact email@example.com.
About BioDuro, LLC
BioDuro is a leading, global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery services spanning target identification to IND filing, through to manufacture of drug substance for clinical trials. With depth and breadth of therapeutic expertise in small and large molecule discovery, development and scale up, combined with unique technology platforms such as high content 3D drug screening and bioavailability enhancement of insoluble compounds, BioDuro is well positioned to help biopharmaceutical partners significantly accelerate their lead discovery programs, and de-risk development programs for higher value outcomes. Visit www.bioduro.com